CD274 and cancer: The expression of PD-L1 in tumor and/or tumor-infiltrating lymphocytes assessed by immunohistochemistry (IHC) is an established biomarker to predict efficacy in the treatment of ICIs across many cancer types including melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer (9, 11).